Nicotinamide Riboside Improves Skin Flap Survival in Rats
NR protected skin flaps in rats and boosted cellular recycling, pointing to a possible tissue repair application—not proven benefits in humans.
Summary
Nicotinamide riboside, or NR, is a supplement ingredient that helps cells produce NAD+, a molecule involved in energy use and cellular maintenance. Researchers tested NR in human blood vessel cells exposed to interrupted oxygen and fuel supplies, and in rats with surgically created skin flaps. NR reduced cell injury and improved flap survival in rats. These effects accompanied increased cellular recycling, stronger blood vessel growth responses, and fewer changes linked to an iron-dependent form of cell death. Experiments involving two regulatory proteins, SIRT1 and FOXO1, supported their involvement in the recycling response. The findings suggest a possible tissue protection application, not proof that NR improves recovery or slows aging in humans. This summary relies on the abstract, which does not report doses, sample sizes, or numerical benefits.
Detailed Summary
Nicotinamide riboside, or NR, is a supplement ingredient that helps cells make NAD+, a molecule involved in energy metabolism and cellular maintenance. Researchers tested whether it could protect transplanted skin from damage caused by an interrupted blood supply. This surgical problem can cause tissue death and undermine reconstructive procedures.
The study combined experiments in human blood vessel lining cells with a rat model of skin flap injury. Cells underwent oxygen and glucose deprivation followed by restoration, mimicking aspects of interrupted and restored circulation. Researchers also altered two regulatory proteins, SIRT1 and FOXO1, to investigate how NR might influence cellular recycling, known as autophagy.
NR reduced injury in the cultured cells, increased their NAD+ levels, and enhanced autophagy. Experiments found an association between SIRT1 and FOXO1. Reducing FOXO1 partly weakened the autophagy response associated with NR, while increasing FOXO1 partly restored that response after SIRT1 was reduced. These results support involvement of this signaling pathway, without establishing it as the only explanation.
In rats, NR improved skin flap survival. This improvement accompanied stronger blood vessel growth responses, changes linked to autophagy, and fewer changes associated with ferroptosis, an iron dependent form of cell death. The findings suggest a possible tissue protection application for NR, rather than demonstrating slower aging or longer life.
However, this summary is based on the abstract only. It does not provide sample sizes, NR doses, treatment timing, numerical effect sizes, or enough detail to assess randomization and blinding. Human cells in a laboratory are not evidence of benefit in patients, and rat results may not translate to surgery in humans. The study does not establish a useful supplement dose, clinical safety, or effectiveness for wound healing. Patients should not start NR to improve surgical recovery based on these findings; controlled human trials would still be needed first.
Key Findings
- NR improved skin flap survival in rats; the abstract does not quantify the benefit.
- In human blood vessel cells, NR reduced injury after oxygen and glucose deprivation followed by restoration.
- Manipulating SIRT1 and FOXO1 supported their involvement in NR-associated cellular recycling.
- Rat tissue showed stronger blood vessel growth responses and fewer ferroptosis-related changes.
- These preclinical findings do not establish a human supplement dose or justify taking NR for surgical recovery.
Methodology
Researchers combined oxygen-glucose deprivation/reperfusion experiments in human umbilical vein endothelial cells with a rat model of ischemic skin flaps. Protein association assays and experiments reducing or increasing SIRT1 and FOXO1 activity examined their involvement in NR-associated autophagy.
Study Limitations
This summary is based on the abstract only, which does not report sample sizes, dosing, numerical effect sizes, or sufficient information about randomization and blinding. Cell and rat experiments cannot establish human efficacy or safety, and the study did not test aging or lifespan outcomes.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: